Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.30 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2818400 | 1.00 | HDAC3 (0.37) | HDAC3ENPP3ENPP1 | |
| SCHEMBL2818395 | 1.00 | HDAC3 (0.37) | HDAC3ENPP3ENPP1 | |
| SCHEMBL2167997 | 0.80 | HDAC3 (0.38) | HDAC3ENPP3ENPP1 | |
| SCHEMBL2168005 | 0.80 | HDAC3 (0.38) | HDAC3ENPP3ENPP1 | |
| SCHEMBL231196 | 0.74 | — | — | |
| SCHEMBL4141187 | 0.73 | HDAC3 (0.37) | HDAC3ENPP3ENPP1 | |
| SCHEMBL2818539 | 0.71 | MEN1 (0.37) | HDAC3 | |
| SCHEMBL2818543 | 0.71 | MEN1 (0.37) | HDAC3 | |
| SCHEMBL29208074 | 0.69 | — | — | |
| SCHEMBL14620132 | 0.68 | HDAC3 (0.33) | HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168179-A1 | 6-ALKENYL-, 6-ALKINYL- AND 6-EPOXY-EPOTHILONE DERIVATIVES, PROCESS FOR THEIR PRODUCTION, AND THEIR USE IN PHARMACEUTICAL PREPARATIONS | KLAR ULRICH | 2010-07-01 | — | — | US | disclosed |
| US-7700621-B2 | E.g., 4-(2-methyl-3-oxo-hept-6-en-2-yl)-2,2-dimethyl-[1,3]-dioxane chemical intermediate; chemical/metabolic stabilization of microtubuli; antitumor, -carcinogenic agents; malignant melanoma, acute lymphocytic/myelocytic leukemia; angiogenesis inhibitors; antiinflammatory/-arthritic agents; psoriasis | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-20 | — | — | US | disclosed |
| US-7645891-B2 | E.g., 4-(2-methyl-3-oxo-hept-6-en-2-yl)-2,2-dimethyl-[1,3]-dioxane chemical intermediate; chemical/metabolic stabilization of microtubuli; antitumor, -carcinogenic agents; malignant melanoma, acute lymphocytic/myelocytic leukemia; angiogenesis inhibitors; antiinflammatory/-arthritic agents; psoriasis | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-01-12 | — | — | US | disclosed |
| EP-1173441-B1 | 6-ALKENYL-, 6-ALKINYL- AND 6-EPOXY-EPOTHILONE DERIVATIVES, PROCESS FOR THEIR PRODUCTION, AND THEIR USE IN PHARMACEUTICAL PREPARATIONS | BAYER SCHERING PHARMA AG (DE) | 2009-08-26 | — | — | EP | disclosed |
| US-7125893-B1 | 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations | SCHERING AG (DE) | 2006-10-24 | — | — | US | disclosed |
| US-20060046997-A1 | 6-Alkenyl -, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2006-03-02 | — | — | US | disclosed |
| US-20050113429-A1 | 6-Alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2005-05-26 | — | — | US | disclosed |
| EP-1173441-A1 | 6-ALKENYL-, 6-ALKINYL- AND 6-EPOXY-EPOTHILONE DERIVATIVES, PROCESS FOR THEIR PRODUCTION, AND THEIR USE IN PHARMACEUTICAL PREPARATIONS | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-01-23 | — | — | EP | disclosed |
| WO-2000066589-A1 | 6-ALKENYL-, 6-ALKINYL- AND 6-EPOXY-EPOTHILONE DERIVATIVES, PROCESS FOR THEIR PRODUCTION, AND THEIR USE IN PHARMACEUTICAL PREPARATIONS | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060046997-A1 | 6-Alkenyl -, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations | TUBB6, CCNB1, TUBB | HDAC3 3941/4885ENPP3 1930/4885ENPP1 1840/4885 |
| US-20100168179-A1 | 6-ALKENYL-, 6-ALKINYL- AND 6-EPOXY-EPOTHILONE DERIVATIVES, PROCESS FOR THEIR PRODUCTION, AND THEIR USE IN PHARMACEUTICAL PREPARATIONS | TUBB6, CCNB1, TUBB | HDAC3 3941/4885ENPP3 1930/4885ENPP1 1840/4885 |
| US-20050113429-A1 | 6-Alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations | TUBB6, CCNB1, TUBB | HDAC3 3952/4885ENPP3 1961/4885ENPP1 1884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.